Macrogenics Inc SEC Filings

Thomas Spitznagel, Sr. VP Technical Ops at MacroGenics, Inc. (MGNX), acquired 30,000 shares of common stock through the exercise of employee stock options on 08/15/2025. The options had an exercise price of $1.58 and convert to 30,000 shares upon exercise. After the reported transaction, 30,000 shares are beneficially owned directly. The option grant vests 25% one year after the grant date with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

MacroGenics insider award: Senior Vice President and General Counsel Jeffrey Stuart Peters received an employee stock option grant for 30,000 shares on 08/15/2025. The option has an exercise price of $1.58, vests 25% after one year with the remaining 75% vesting in 12 substantially equal quarterly installments, and expires on 08/15/2035. Following the reported transaction Mr. Peters beneficially owns 30,000 common shares subject to the option on a direct basis. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Scott Koenig, a director of MacroGenics, Inc. (MGNX), reported vested restricted stock units (RSUs) on 08/13/2025 that converted into common stock. The Form 4 shows two separate RSU vesting transactions under code M, totaling 52,829 RSUs (21,165 and 31,664) with a reported price of $0 per unit because each RSU represents a contingent right to one share. The filing states these vestings occurred pursuant to a Separation and Consulting Agreement that caused 50% of each outstanding unvested RSU to vest, and that vested shares will be delivered as soon as practicable. The Form is signed by an attorney-in-fact on 08/15/2025. The reported beneficial ownership figures following the transactions are shown as 798,580 and 830,244 shares on the two reporting lines.

Insider option grant to CEO/Director MacroGenics reported that Eric Blasius Risser, who serves as President and CEO and a director, was granted an employee stock option covering 550,000 shares of common stock with an exercise price of $1.66. The option was granted with an exercise schedule that vests 25% one year after grant and the remaining 75% in 12 substantially equal quarterly installments thereafter. The options are exercisable through 08/13/2035 and are directly owned by the reporting person following the transaction.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.

The Frazier Life Sciences reporting group disclosed specific holdings in MacroGenics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 1,549,193 shares representing 2.5% of the 63,090,323 shares outstanding used for the percentage calculation. Other reporting entities hold 925,809 shares (1.5%), 575,150 shares (0.9%) and 125,513 shares (0.2%).

The filing states that voting and dispositive power for these shares is shared rather than sole and corrects prior attributions by clarifying that members of certain investment committees are not attributed beneficial ownership of the securities held by the respective funds. The statement also notes the reporters do not admit broader beneficial ownership or group status beyond what is disclosed.

MacroGenics appointed Eric Risser as President, Chief Executive Officer and elected him as a Class I director with a term expiring at the 2026 annual meeting. Mr. Risser, previously the company’s Chief Operating Officer, became the company’s principal executive officer effective August 13, 2025.

The company agreed an amended employment arrangement providing a $625,000 annual base salary, eligibility for annual incentive pay up to 60% of base salary, and a stock option to purchase 550,000 shares at the closing price on the effective date. Termination protections include cash severance (typically 1.0x salary plus 1.0x target bonus prorated, increased to 1.5x for change-of-control scenarios), COBRA premium coverage up to 18 months, and acceleration of unvested equity upon certain change-of-control terminations.

On 07/07/2025, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, filed a Schedule 13G revealing a 9,929,963-share position in MacroGenics, Inc. (MGNX) as of 06/01/2025. The stake equals 15.7 % of the company’s outstanding common stock. Both entities are incorporated in Switzerland and report shared voting and dispositive power over the entire holding, with zero sole voting or dispositive authority. Bellevue is classified as a “HC, CO” (parent holding company/control person) and Bellevue Asset Management AG as “CO.”

The certification states that the shares were acquired and are held in the ordinary course of business and are not intended to influence control of MacroGenics. This filing increases transparency around MacroGenics’ ownership structure and highlights a sizeable passive investment from a regulated Swiss financial institution.